In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
T-3811, the free base of T-3811ME (BMS-284756), a new des-F(6)-quinolone, showed a potent in vitro activity (MIC at which 90% of the isolates tested are inhibited [MIC(90)], 0.0313 microg/ml) against Mycoplasma pneumoniae. The MIC(90) of T-3811 was 4-fold higher than that of clarithromycin but was 4- to 8-fold lower than those of trovafloxacin, gatifloxacin, gemifloxacin, and moxifloxacin and was 16- to 32-fold lower than those of levofloxacin, ciprofloxacin, and minocycline. In an experimental M. pneumoniae pneumonia model in hamsters, after the administration of T-3811ME (20 mg/kg of body weight as T-3811, once daily, orally) for 5 days, the reduction of viable cells of M. pneumoniae in bronchoalveolar lavage fluid was greater than those of trovafloxacin, levofloxacin, and clarithromycin (20 and 40 mg/kg, orally) (P < 0.05).
Takahata
M
M
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan. MASAHIRO_TAKAHATA@toyama-chemical.co.jp
Shimakura
M
M
Hori
R
R
Kizawa
K
K
Todo
Y
Y
Minami
S
S
Watanabe
Y
Y
Narita
H
H
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D006224:Cricetinae; D024841:Fluoroquinolones; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use*; D054833:Isoindoles; D008168:Lung / Q000382:microbiology; D008297:Male; D008647:Mesocricetus; D008826:Microbial Sensitivity Tests; D009177:Mycoplasma pneumoniae / Q000187:drug effects*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy* / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007211:Indoles; D054833:Isoindoles; D015363:Quinolones; C118960:T 3811ME